Soligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent Accomplishments Current Cash Resources Total $8.1 Million Princeton, NJ - August 12, 2013 - Soligenix, Inc. , a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an ... (more)
More...
More...